The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?

Saved in:
Bibliographic Details
Published in:Archivos de bronconeumología 2002-11, Vol.38 (11), p.547; author reply 547-547; author reply 548
Main Authors: Roig, J, Martínez Benazet, J, Casal, J
Format: Article
Language:Spanish
Subjects:
Anti-Infective Agents - therapeutic use
Humans
Levofloxacin
Ofloxacin - therapeutic use
Pulmonary Disease, Chronic Obstructive - drug therapy
Respiratory Tract Infections - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 547; author reply 548
container_issue 11
container_start_page 547; author reply 547
container_title Archivos de bronconeumología
container_volume 38
creator Roig, J
Martínez Benazet, J
Casal, J
description
doi_str_mv 10.1016/S0300-2896(02)75286-1
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72690598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72690598</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-afa5574be3a8f99405178a5ec0b5f037e76f9e31727d612e4846c6f1bfc1b20f3</originalsourceid><addsrcrecordid>eNo9kMtKxDAYhbNQvD-CkpUoWM2lSVs3IuNtYEBBXZc0_cNE0qYmqTpP46ta8bI6cM7HtzgI7VNySgmVZ4-EE5KxspJHhB0XgpUyo2to67_eRNsxvhDCBM_ZBtqkLOeCM76FPp-WgMcI2Bvs4M0b5z-Utj02PuA0bdANNlitHE4BVOqgT98sTBSERiXr-_hddNa1J1gvg--txrP7h6tzPI_YJvwyxmSNhRZP2rFvIWRSZCtQIWbetXiYJJM14neblrj3WPvOh8a2Nq0udtG6US7C3m_uoOeb66fZXba4v53PLhfZQHmVMmWUEEXeAFelqaqcCFqUSoAmjTCEF1BIUwGnBStaSRnkZS61NLQxmjaMGL6DDn-8Q_CvI8RUdzZqcE714MdYF0xWRFTlBB78gmPTQVsPwXYqrOq_S_kX-Hx5iQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72690598</pqid></control><display><type>article</type><title>The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?</title><source>ScienceDirect Journals</source><creator>Roig, J ; Martínez Benazet, J ; Casal, J</creator><creatorcontrib>Roig, J ; Martínez Benazet, J ; Casal, J</creatorcontrib><identifier>ISSN: 0300-2896</identifier><identifier>DOI: 10.1016/S0300-2896(02)75286-1</identifier><identifier>PMID: 12435323</identifier><language>spa</language><publisher>Spain</publisher><subject>Anti-Infective Agents - therapeutic use ; Humans ; Levofloxacin ; Ofloxacin - therapeutic use ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Respiratory Tract Infections - drug therapy</subject><ispartof>Archivos de bronconeumología, 2002-11, Vol.38 (11), p.547; author reply 547-547; author reply 548</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12435323$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roig, J</creatorcontrib><creatorcontrib>Martínez Benazet, J</creatorcontrib><creatorcontrib>Casal, J</creatorcontrib><title>The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?</title><title>Archivos de bronconeumología</title><addtitle>Arch Bronconeumol</addtitle><subject>Anti-Infective Agents - therapeutic use</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Ofloxacin - therapeutic use</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Respiratory Tract Infections - drug therapy</subject><issn>0300-2896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNo9kMtKxDAYhbNQvD-CkpUoWM2lSVs3IuNtYEBBXZc0_cNE0qYmqTpP46ta8bI6cM7HtzgI7VNySgmVZ4-EE5KxspJHhB0XgpUyo2to67_eRNsxvhDCBM_ZBtqkLOeCM76FPp-WgMcI2Bvs4M0b5z-Utj02PuA0bdANNlitHE4BVOqgT98sTBSERiXr-_hddNa1J1gvg--txrP7h6tzPI_YJvwyxmSNhRZP2rFvIWRSZCtQIWbetXiYJJM14neblrj3WPvOh8a2Nq0udtG6US7C3m_uoOeb66fZXba4v53PLhfZQHmVMmWUEEXeAFelqaqcCFqUSoAmjTCEF1BIUwGnBStaSRnkZS61NLQxmjaMGL6DDn-8Q_CvI8RUdzZqcE714MdYF0xWRFTlBB78gmPTQVsPwXYqrOq_S_kX-Hx5iQ</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Roig, J</creator><creator>Martínez Benazet, J</creator><creator>Casal, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?</title><author>Roig, J ; Martínez Benazet, J ; Casal, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-afa5574be3a8f99405178a5ec0b5f037e76f9e31727d612e4846c6f1bfc1b20f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2002</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Ofloxacin - therapeutic use</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Respiratory Tract Infections - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roig, J</creatorcontrib><creatorcontrib>Martínez Benazet, J</creatorcontrib><creatorcontrib>Casal, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de bronconeumología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roig, J</au><au>Martínez Benazet, J</au><au>Casal, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?</atitle><jtitle>Archivos de bronconeumología</jtitle><addtitle>Arch Bronconeumol</addtitle><date>2002-11</date><risdate>2002</risdate><volume>38</volume><issue>11</issue><spage>547; author reply 547</spage><epage>547; author reply 548</epage><pages>547; author reply 547-547; author reply 548</pages><issn>0300-2896</issn><cop>Spain</cop><pmid>12435323</pmid><doi>10.1016/S0300-2896(02)75286-1</doi></addata></record>
fulltext fulltext
identifier ISSN: 0300-2896
ispartof Archivos de bronconeumología, 2002-11, Vol.38 (11), p.547; author reply 547-547; author reply 548
issn 0300-2896
language spa
recordid cdi_proquest_miscellaneous_72690598
source ScienceDirect Journals
subjects Anti-Infective Agents - therapeutic use
Humans
Levofloxacin
Ofloxacin - therapeutic use
Pulmonary Disease, Chronic Obstructive - drug therapy
Respiratory Tract Infections - drug therapy
title The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A19%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20levofloxacin%20for%20the%20empirical%20treatment%20of%20exacerbations%20of%20mild,%20chronic%20COPD:%20Is%20it%20justified%20in%20under-65-years-old%20patients%20with%20no%20comorbidity?&rft.jtitle=Archivos%20de%20bronconeumolog%C3%ADa&rft.au=Roig,%20J&rft.date=2002-11&rft.volume=38&rft.issue=11&rft.spage=547;%20author%20reply%20547&rft.epage=547;%20author%20reply%20548&rft.pages=547;%20author%20reply%20547-547;%20author%20reply%20548&rft.issn=0300-2896&rft_id=info:doi/10.1016/S0300-2896(02)75286-1&rft_dat=%3Cproquest_pubme%3E72690598%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p139t-afa5574be3a8f99405178a5ec0b5f037e76f9e31727d612e4846c6f1bfc1b20f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72690598&rft_id=info:pmid/12435323&rfr_iscdi=true